Genomic and biochemical clues behind meningioma race differences and outcomes
Official title: Project 1: Genomic and biochemical mechanisms underlying meningioma race disparity across social and structural drivers of health
Funded at University of California, San Francisco · NIH-11378043 · Data updated 2026-11-12
This grant aims to uncover biological and environmental factors that cause differences in meningioma occurrence and treatment results across racial groups, with the goal of improving care for patients affected by this brain tumor.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $422,187 |
| NIH project number | 5U54CA302452-02 |
| Project ID | NIH-11378043 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals diagnosed with meningioma, especially Black patients and those with higher-risk molecular features, may be eligible for related studies or future trials.
✕Less likely to help
Patients without meningioma or without the specific molecular features studied may not directly benefit from these findings.
What this research studies
Meningiomas are more common in Black individuals and can be harder to treat when aggressive. This project will integrate genomic and biochemical analyses with real-world patient data to identify biomarkers and mechanisms that explain racial disparities in incidence and recurrence. By combining multi-omics profiling from many institutions with population data, researchers hope to pinpoint targets that could guide personalized therapies and better prediction of outcomes. The work will involve experts in bioinformatics, biology, and clinical data to translate findings into clinically useful insights for patients and clinicians. The grant spans five years and supports a collaborative effort across multiple centers, centered at UCSF.
Why it matters
Potential benefit: If successful, patients with meningioma could receive more precise diagnoses and tailored treatments that reduce recurrence and improve survival across racial groups.
How similar studies have gone: Previous multi-institution profiling has identified biomarkers; this project builds on those findings with a broader racial disparity focus.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Raleigh, David R — University of California, San Francisco
- Study coordinator: Raleigh, David R
Related research
Other NIH-funded projects on the same topics.
-
Meningioma biology and new therapies guided by molecular profiling
A large, multi-institution study is exploring how meningiomas grow and respond to treatment, using advanced molecular profiling to find safer, more effective ways to manage them.
-
Biomarker-based guidance to predict meningioma outcomes and radiotherapy response
A gene-based test is being developed to help predict how meningioma tumors will behave and how patients may respond to radiotherapy.
-
Meningioma radiotherapy response: understanding gene clues and how to tailor treatment
A short research project will study why some meningioma tumors respond differently to radiotherapy by looking at gene activity and how it affects treatment outcomes.
-
How the MN1 protein drives aggressive acute myeloid leukemia
This project looks at how the MN1 protein and its partner BAF complex keep leukemia genes active in people with acute myeloid leukemia to reveal new treatment targets.
-
How meningiomas change over time and new treatment targets
This project looks for molecular signs that predict which meningiomas will come back and finds drug targets to help people with aggressive or recurrent tumors.
-
Finding new ways to treat meningioma brain tumors
This project looks for new medicine targets to help patients with meningioma, a common type of brain tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.